For the roughly one billion people worldwide living with migraine, finding an acute treatment that works reliably — not just once, but attack after attack — is the defining clinical challenge. A new CGRP receptor antagonist class has reshaped expectations, and real-world data now offer a more honest test than controlled trials can provide.
The CONFIDENCE study enrolled 416 U.S. adults with 3–14 migraine headache days per month, all of whom had an active rimegepant prescription and tracked outcomes via the Migraine Buddy app over 28 days. Collectively, participants recorded 2,169 rimegepant-treated attacks — a median of seven per person — generating a granular dataset on consistency rather than single-episode efficacy. The cohort was predominantly female (91%) and White (90%), with 84% concurrently using at least one preventive migraine therapy. Three primary outcomes were tracked: meaningful pain relief (MPR) within two hours, meaningful improvement in function (MIF) within two hours, and patient-reported treatment satisfaction. Findings showed that positive outcomes were replicated across multiple attacks at both the population and individual participant level, suggesting rimegepant's benefit is not an isolated occurrence.
This consistency data fills a genuine gap. Phase III trials for gepants, including rimegepant, established single-attack efficacy compared to placebo, but they could not speak to whether the same patient benefits reliably over weeks of use. The CONFIDENCE results are meaningful because variability is actually the norm in migraine pharmacotherapy — triptans, for example, show substantial within-person inconsistency. That said, several limitations temper enthusiasm: the cohort skews heavily White and female, limiting generalizability; there is no comparator arm; and recruitment through a migraine-specific app likely selects for engaged, health-literate patients who may perform better on any therapy. The high rate of concurrent preventive therapy (84%) also makes it difficult to isolate rimegepant's independent contribution. Incrementally important rather than paradigm-shifting, this study strengthens the case for rimegepant as a reliable acute option — particularly for patients who have failed triptans.